KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Debt to Equity (2022 - 2026)

Adaptive Biotechnologies' Debt to Equity history spans 4 years, with the latest figure at $0.6 for Q4 2025.

  • On a quarterly basis, Debt to Equity fell 8.79% to $0.6 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.6, a 8.79% decrease, with the full-year FY2025 number at $0.6, down 8.79% from a year prior.
  • Debt to Equity hit $0.6 in Q4 2025 for Adaptive Biotechnologies, down from $0.65 in the prior quarter.
  • Over the last five years, Debt to Equity for ADPT hit a ceiling of $0.74 in Q2 2025 and a floor of $0.27 in Q4 2022.
  • Historically, Debt to Equity has averaged $0.55 across 4 years, with a median of $0.59 in 2024.
  • Biggest five-year swings in Debt to Equity: soared 65.21% in 2024 and later dropped 8.79% in 2025.
  • Tracing ADPT's Debt to Equity over 4 years: stood at $0.27 in 2022, then soared by 56.91% to $0.42 in 2023, then skyrocketed by 55.13% to $0.66 in 2024, then decreased by 8.79% to $0.6 in 2025.
  • Business Quant data shows Debt to Equity for ADPT at $0.6 in Q4 2025, $0.65 in Q3 2025, and $0.74 in Q2 2025.